The role of stem cell transplantation in Waldenstrom's macroglobulinemia

Rajshekhar Chakraborty, Eli Muchtar, Morie Gertz

Research output: Contribution to journalReview article

Abstract

Waldenstrom's macroglobulinemia (WM) is an indolent B-cell lymphoma, which is highly chemosensitive, with an overall response rate over 90% to novel agents. However, most patients eventually relapse after response to first-line chemotherapy, necessitating further treatment. The possibility of long-lasting remission after high-dose cytotoxic chemotherapy followed by stem cell rescue is high in WM due to the chemosensitive nature of the disease and lower proliferative activity compared to multiple myeloma. In this paper, we have reviewed current evidence on autologous (auto-) and allogeneic (allo-) stem cell transplantation (SCT) in WM. Auto-SCT can be safely performed in WM and is recommended as second-line treatment or beyond in eligible patients. It is associated with extremely low transplant-related mortality. Allo-SCT is effective in WM with incremental benefit due to graft-versus-WM effect, but is associated with high non-relapse mortality of 30%, hence should be preferably considered investigational as part of clinical trials in selected patients who have exhausted other treatment options.

Original languageEnglish (US)
Pages (from-to)229-240
Number of pages12
JournalBest Practice and Research: Clinical Haematology
Volume29
Issue number2
DOIs
StatePublished - Jun 1 2016

Fingerprint

Waldenstrom Macroglobulinemia
Stem Cell Transplantation
Stem cells
Chemotherapy
Transplants
Grafts
Drug Therapy
Mortality
Cells
B-Cell Lymphoma
Multiple Myeloma
Stem Cells
Therapeutics
Clinical Trials
Recurrence

Keywords

  • Allogeneic stem cell transplantation
  • Autologous stem cell transplantation
  • Waldenstrom's macroglobulinemia

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

The role of stem cell transplantation in Waldenstrom's macroglobulinemia. / Chakraborty, Rajshekhar; Muchtar, Eli; Gertz, Morie.

In: Best Practice and Research: Clinical Haematology, Vol. 29, No. 2, 01.06.2016, p. 229-240.

Research output: Contribution to journalReview article

@article{26cba2596da247c78dd2c787d96367f3,
title = "The role of stem cell transplantation in Waldenstrom's macroglobulinemia",
abstract = "Waldenstrom's macroglobulinemia (WM) is an indolent B-cell lymphoma, which is highly chemosensitive, with an overall response rate over 90{\%} to novel agents. However, most patients eventually relapse after response to first-line chemotherapy, necessitating further treatment. The possibility of long-lasting remission after high-dose cytotoxic chemotherapy followed by stem cell rescue is high in WM due to the chemosensitive nature of the disease and lower proliferative activity compared to multiple myeloma. In this paper, we have reviewed current evidence on autologous (auto-) and allogeneic (allo-) stem cell transplantation (SCT) in WM. Auto-SCT can be safely performed in WM and is recommended as second-line treatment or beyond in eligible patients. It is associated with extremely low transplant-related mortality. Allo-SCT is effective in WM with incremental benefit due to graft-versus-WM effect, but is associated with high non-relapse mortality of 30{\%}, hence should be preferably considered investigational as part of clinical trials in selected patients who have exhausted other treatment options.",
keywords = "Allogeneic stem cell transplantation, Autologous stem cell transplantation, Waldenstrom's macroglobulinemia",
author = "Rajshekhar Chakraborty and Eli Muchtar and Morie Gertz",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.beha.2016.08.018",
language = "English (US)",
volume = "29",
pages = "229--240",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - The role of stem cell transplantation in Waldenstrom's macroglobulinemia

AU - Chakraborty, Rajshekhar

AU - Muchtar, Eli

AU - Gertz, Morie

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Waldenstrom's macroglobulinemia (WM) is an indolent B-cell lymphoma, which is highly chemosensitive, with an overall response rate over 90% to novel agents. However, most patients eventually relapse after response to first-line chemotherapy, necessitating further treatment. The possibility of long-lasting remission after high-dose cytotoxic chemotherapy followed by stem cell rescue is high in WM due to the chemosensitive nature of the disease and lower proliferative activity compared to multiple myeloma. In this paper, we have reviewed current evidence on autologous (auto-) and allogeneic (allo-) stem cell transplantation (SCT) in WM. Auto-SCT can be safely performed in WM and is recommended as second-line treatment or beyond in eligible patients. It is associated with extremely low transplant-related mortality. Allo-SCT is effective in WM with incremental benefit due to graft-versus-WM effect, but is associated with high non-relapse mortality of 30%, hence should be preferably considered investigational as part of clinical trials in selected patients who have exhausted other treatment options.

AB - Waldenstrom's macroglobulinemia (WM) is an indolent B-cell lymphoma, which is highly chemosensitive, with an overall response rate over 90% to novel agents. However, most patients eventually relapse after response to first-line chemotherapy, necessitating further treatment. The possibility of long-lasting remission after high-dose cytotoxic chemotherapy followed by stem cell rescue is high in WM due to the chemosensitive nature of the disease and lower proliferative activity compared to multiple myeloma. In this paper, we have reviewed current evidence on autologous (auto-) and allogeneic (allo-) stem cell transplantation (SCT) in WM. Auto-SCT can be safely performed in WM and is recommended as second-line treatment or beyond in eligible patients. It is associated with extremely low transplant-related mortality. Allo-SCT is effective in WM with incremental benefit due to graft-versus-WM effect, but is associated with high non-relapse mortality of 30%, hence should be preferably considered investigational as part of clinical trials in selected patients who have exhausted other treatment options.

KW - Allogeneic stem cell transplantation

KW - Autologous stem cell transplantation

KW - Waldenstrom's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84994478254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994478254&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2016.08.018

DO - 10.1016/j.beha.2016.08.018

M3 - Review article

VL - 29

SP - 229

EP - 240

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 2

ER -